Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Interest & Investment Income (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Interest & Investment Income for 13 consecutive years, with $9.5 million as the latest value for Q4 2025.

  • Quarterly Interest & Investment Income fell 14.62% to $9.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $37.4 million through Dec 2025, down 19.91% year-over-year, with the annual reading at $37.4 million for FY2025, 19.91% down from the prior year.
  • Interest & Investment Income for Q4 2025 was $9.5 million at Madrigal Pharmaceuticals, down from $10.3 million in the prior quarter.
  • The five-year high for Interest & Investment Income was $14.2 million in Q2 2024, with the low at $52000.0 in Q4 2021.
  • Average Interest & Investment Income over 5 years is $5.3 million, with a median of $3.7 million recorded in 2023.
  • The sharpest move saw Interest & Investment Income crashed 92.71% in 2021, then skyrocketed 5372.46% in 2023.
  • Over 5 years, Interest & Investment Income stood at $52000.0 in 2021, then skyrocketed by 1969.23% to $1.1 million in 2022, then soared by 732.06% to $9.0 million in 2023, then grew by 23.75% to $11.1 million in 2024, then fell by 14.62% to $9.5 million in 2025.
  • According to Business Quant data, Interest & Investment Income over the past three periods came in at $9.5 million, $10.3 million, and $8.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.